BioLineRx Ltd. (BLRX)
$2.17+0.00%Close
SELLCRISIS · day 12
Key stats
Short interest · FINRA settlement 2026-09-30
- Market cap
- $9M
- Beta
- 0.70
- P/E (TTM)
- -1.26
- Short % float
- 3.50%
- Days to cover
- 11.1
- SI change
- -0.2%
- 1W
- -5.24%
- 1M
- -10.70%
- vs SPY 1W
- -5.10%
- vs SPY 1M
- -13.21%
Industry peers
FMP comparable companies · ranked by market cap
Prediction markets
Kalshi · Polymarket · … linked
Loading markets…
FUNDAMENTALS
[SCORES & PROFILE]
- FUND
- 0
- VALUE
- 6
- GROWTH
- 19
- GARP
- 4
- TYPE
- Balanced
Composite of Value · Growth · GARP
ROIC-28.3%
REV YoY-
ROE-47.2%
EPS YoY-
ROA-24.2%
GROSS70
OP-877
NET-576
[VALUATION]
P/E TTM-1.26
P/E FWD-
SECTOR PE20.34
INDUSTRY PE13.84
P/B0.76
P/FCF-
EV/EBITDA-1.20
EV/EBIT-
PEG-
FCF YIELD-
RISK
INT COV-
D/E58.06
ALTMAN Z-
CURR RATIO1.20
ND/EBITDA-
BETA0.70
Company news
FAQ
- What is LOPJLB’s current signal on BLRX?
- LOPJLB’s latest quantitative signal on BioLineRx Ltd. (BLRX) is SELL in a CRISIS regime. Signals are updated daily.
- What market regime is BLRX in?
- BioLineRx Ltd. (BLRX) is currently classified in the CRISIS HMM market regime on LOPJLB.
- What does BioLineRx Ltd. (BLRX) do?
- BioLineRx Ltd., an Israeli biopharmaceutical firm established in 2003 and based in Hevel Modi'in, focuses its clinical-stage development efforts primarily on oncology. Their leading investigational product, Motixafortide, a peptide, has successfully concluded pivotal Phase 3 clinical trials for mobilizing stem cells in autologous transplants, and Phase 2a trials targeting pancreatic cancer. Thi…